Borders, international ethics and standards
Valid research findings need to hold across diverse populations. Genetic variation, environmental factors, and cultural background all influence how conditions present and how interventions perform. A finding from a study conducted entirely within one demographic may not translate reliably to others. This is why multi-country research matters, and why navigating the ethics and regulatory landscape across borders is a genuine operational challenge, not just an administrative inconvenience layered on top of the real work.
It's tempting to treat ethics and regulatory variation as paperwork to get through on the way to the actual study. That framing undersells it. The specific protections a research ethics body requires, and the specific things it's most sensitive to, often reflect real historical context in that country or region, meaning the "extra" requirement in one jurisdiction is frequently the direct answer to a problem that has already happened there once.
The scale of the problem
The US Department of Health and Human Services attempts to capture this complexity in its International Compilation of Human Research Standards, which catalogues well over 1,000 individual laws, regulations, and guidelines across more than 100 countries, alongside standards from international and regional organisations. Those standards are organised into categories covering:
- General research requirements (applicable to most human subjects research)
- Drugs and devices
- Clinical trial registries
- Research injury
- Social and behavioural research
- Privacy and data protection
- Human biological materials
- Genetic research
- Embryos, stem cells, and cloning
The compilation is updated periodically to reflect evolving standards, and the sheer scale of it, over a thousand distinct instruments across a hundred-plus jurisdictions, is worth sitting with for a moment. No single team is realistically going to memorise the requirements for every country their study might touch. The practical use of the compilation isn't comprehensive mastery. It's knowing it exists as a reliable starting point for the specific countries your study actually involves, and building time into your planning to consult it properly rather than assuming requirements are broadly similar everywhere.
Ethics committee terminology
Participant protection in research is overseen by ethics committees, but the name for that body varies significantly depending on where the work is taking place:
| Acronym | Full name | Region or context |
|---|---|---|
| IRB | Institutional Review Board | United States |
| REB | Research Ethics Board | Canada |
| EC | Ethics Committee | Europe (general term) |
| REC | Research Ethics Committee | United Kingdom |
| ERB | Ethics Review Board | International organisations |
| IBC | Institutional Bioethics Committee | Latin America |
| HREC | Human Research Ethics Committee | Australia |
| NEC | National Ethics Committee | National level, various countries |
| IEC | Independent Ethics Committee | Pharmaceutical industry context |
These bodies perform broadly similar functions: reviewing risk to participants, checking consent materials are adequate, and confirming the science justifies the study being done at all. But their specific requirements, timelines, and documentation expectations differ meaningfully, and a document package that satisfies an IRB in the US will rarely transfer unmodified to an EC in Europe or an HREC in Australia. Building in sufficient time for ethics review in each jurisdiction is one of the most commonly underestimated tasks in multi-country study planning, and it compounds: a delay in one country's ethics review can hold up site activation everywhere else if the study's overall timeline was built assuming parallel, synchronised approvals.
What this means for planning
Treat each jurisdiction's ethics and regulatory pathway as its own mini-project with its own timeline, rather than a single line item on the overall study plan. Confirm early which category of research your study falls into for each country involved, since the compilation's categorisation (general requirements, genetic research, human biological materials, and so on) often determines which additional standards apply beyond the baseline. And where terminology or process genuinely differs between jurisdictions, document that difference explicitly for your team rather than assuming everyone already knows which acronym applies where they're working.
Multi-country research is one of the more powerful tools available for producing findings that actually generalise. It's also one of the easiest places for a timeline to quietly slip, one jurisdiction at a time, if the ethics landscape isn't treated with the same planning rigour as the science itself.
The teams that handle this well tend to build a local relationship in each country early, someone who can translate not just documents but expectations, rather than trying to manage every jurisdiction remotely through email and generic templates. That local knowledge is usually what closes the gap between what the compilation says on paper and what a specific committee actually expects to see in practice.